Literature DB >> 20479545

Non-Hodgkin's lymphoma: is India ready to incorporate recent advances in day to day practice?

Saraschandra Vallabhajosyula1, Gunjan Baijal, B M Vadhiraja, Donald J Fernandes, M S Vidyasagar.   

Abstract

BACKGROUND: Non Hodgkin's Lymphoma (NHL) cure rates are increasing and morbidities are decreasing, with more active pharmacological agents and technological advancements. In spite of this, India is still battling with the prejudices of an economically and educationally impoverished patient base. METHODS AND
RESULTS: We analyzed NHL cases from 2000 to 2006 using data from case sheets. Of 303 cases, only 100 patients had complete workup and received some form of treatment. For 203 patients, reasons for non-compliance were: financial constraint (119), distance from center (38), inability of physician to provide guarantees of cure (13), poor prognosis/fear of recurrence (28)), preferences for alternate medicine (5). Most common investigations that could not be afforded for staging were whole body CT scans and bone marrow aspiration and biopsy. Thirteen patients were in stage III and 53 in Stage IV. The most common regimen was CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisolone). Forty-five patients did not complete six courses of CHOP and 35 patients had significant delay. Reasons for delay were intermittent availability of cash (35), intolerable toxicities (30), absence of supportive care (21), given-up attitudes (17). Eighty-three patients suffered Grade III/IV debilitating toxicities. Overall survival at five years was 50%.
CONCLUSIONS: NHL in India is no different from the developed world. However, there are disparities in survivorship and outcomes, due to un-affordability and attitudes of the patients. Therefore, we suggest the development of Community Health Insurance Schemes (CHIs), with the hospital as the nodal center to address the above mentioned issues.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479545     DOI: 10.4103/0973-1482.63571

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

1.  Diagnostic Utility of PAX5 in Hodgkin and Non-Hodgkin Lymphoma: A Study from Northern India.

Authors:  Nidhi Johri; Shashikant C U Patne; Mallika Tewari; Mohan Kumar
Journal:  J Clin Diagn Res       Date:  2016-08-01

2.  Serum Lactate Dehydrogenase in Non-Hodgkin's Lymphoma: A Prognostic Indicator.

Authors:  Charu Yadav; Afzal Ahmad; Benedicta D'Souza; Ashish Agarwal; M Nandini; K Ashok Prabhu; Vivian D'Souza
Journal:  Indian J Clin Biochem       Date:  2015-06-21

3.  Immunohistochemical (IHC) Analysis of Non-Hodgkin's Lymphoma (NHL) Spectrum According to WHO/REAL Classification: A Single Centre Experience from Punjab, India.

Authors:  Manisha Sharma; Rahul Mannan; Mohit Madhukar; Sanjay Navani; Mridu Manjari; Tejinder Singh Bhasin; Karamjit Singh Gill
Journal:  J Clin Diagn Res       Date:  2013-01-12

4.  Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis.

Authors:  Partha Sarathi Roy; Shiji John; Sadashiv Karankal; Sadhana Kannan; Preeti Pawaskar; Jayanta Gawande; Bhausaheb Bagal; Navin Khattry; Manju Sengar; Hari Menon; Sumeet Gujral; Reena Nair
Journal:  Indian J Med Paediatr Oncol       Date:  2013-10

Review 5.  Managing the changing burden of cancer in Asia.

Authors:  Rengaswamy Sankaranarayanan; Kunnambath Ramadas; You-lin Qiao
Journal:  BMC Med       Date:  2014-01-08       Impact factor: 8.775

Review 6.  Diabetes, Epstein-Barr virus and extranodal natural killer/T-cell lymphoma in India: Unravelling the plausible nexus.

Authors:  Anita Spadigam; Anita Dhupar; Shaheen Syed; Tajindra Singh Saluja
Journal:  Indian J Med Paediatr Oncol       Date:  2016 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.